A study of GFH375 for KRAS G12D mutated solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new oral medication (GFH375) for people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if the drug can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your cancer must have a specific genetic change called KRAS G12D.
- Your cancer must be advanced or metastatic (spread beyond the original site) and measurable on scans.
- You must be in good enough health to be up and about (able to do light work or be fully active).
- You cannot have had prior treatment with a KRAS G12D inhibitor or active brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral pill called HS-10529 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or slow their growth, and to check its safety.
This trial tests a new drug called GFH375 combined with either cetuximab or chemotherapy for people with advanced solid tumors that have a specific genetic change called KRAS G12D. It's for those whose cancer has worsened after other treatments or who can't have standard therapy.
This trial tests a new targeted pill (GFH375) alone or with another drug for people with a specific gene change (KRAS G12D) in advanced lung cancer. It aims to shrink or slow the cancer, possibly better than current standard treatments.
This study tests a new targeted pill called FMC-376 for people whose cancer has a specific KRAS G12C mutation. The goal is to see if it can shrink tumors or slow their growth when other treatments have stopped working.
This trial tests a new oral drug (GDC-7035) for people with advanced solid tumors that have a specific KRAS mutation (G12D). The drug may be given alone or with other treatments to see if it is safe and helps fight the cancer.
This trial tests two pills together (GH21 and D-1553) for people whose cancer has a specific genetic marker called KRAS G12C. The goal is to see if this combination can shrink tumors or slow cancer growth, especially after other treatments have stopped working.
Hear when a new KRAS G12D Mutations trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.